Search

Filter By:

Life sciences tax planning upheaval: How the OBBBA transforms your strategic approach 

The One Big Beautiful Bill Act (OBBBA) transforms life sciences tax planning by restoring immediate R&E expensing, offering manufacturing incentives, and reshaping strategic decision-making for pharmaceutical, biotech, and medical device companies.

Learn More

R&D tax strategy for Life Sciences companies

Life Sciences companies face growing R&D challenges and costs. Learn how your organization can leverage U.S. and international tax credits to support innovation and reduce expenses.

Learn More

Mastering Gross-to-Net (GTN) challenges in life science: A pathway to success

Life science companies face complex gross-to-net (GTN) challenges, from managing rebates and pricing to ensuring compliance and accurate forecasts. Learn how a strategic approach and support can drive clarity and success.

Learn More

Navigating new challenges: How tariffs, taxes, and R&D regulations are reshaping Biotech 

Biotech companies face evolving tariffs, tax rules, and R&D regulations. Learn key impacts and strategies to stay competitive in a shifting landscape.

Learn More

Life Science Outlook 2025: Navigating transformation in a complex landscape

The life sciences sector stands at a pivotal moment of transformation, driven by technological breakthroughs, evolving market dynamics and shifting …

Learn More

Key policy changes impacting the life science industry

The life science industry stands at a pivotal moment as it anticipates potential shifts in federal policy. With the Trump …

Learn More